Impact of Acquired Immunity and Dose-Dependent Probability of Illness on Quantitative Microbial Risk Assessment

Authors

  • A. H. Havelaar,

    Corresponding author
    1. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands
    2. Division Veterinary Public Health, Institute for Risk Assessment Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands
    • Address correspondence to Arie Havelaar, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, PO Box 1, Bilthoven 3720 BA, the Netherlands; arie.havelaar@rivm.nl.

    Search for more papers by this author
  • A. N. Swart

    1. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands
    Search for more papers by this author

Abstract

Dose-response models in microbial risk assessment consider two steps in the process ultimately leading to illness: from exposure to (asymptomatic) infection, and from infection to (symptomatic) illness. Most data and theoretical approaches are available for the exposure-infection step; the infection-illness step has received less attention. Furthermore, current microbial risk assessment models do not account for acquired immunity. These limitations may lead to biased risk estimates. We consider effects of both dose dependency of the conditional probability of illness given infection, and acquired immunity to risk estimates, and demonstrate their effects in a case study on exposure to Campylobacter jejuni. To account for acquired immunity in risk estimates, an inflation factor is proposed. The inflation factor depends on the relative rates of loss of protection over exposure. The conditional probability of illness given infection is based on a previously published model, accounting for the within-host dynamics of illness. We find that at low (average) doses, the infection-illness model has the greatest impact on risk estimates, whereas at higher (average) doses and/or increased exposure frequencies, the acquired immunity model has the greatest impact. The proposed models are strongly nonlinear, and reducing exposure is not expected to lead to a proportional decrease in risk and, under certain conditions, may even lead to an increase in risk. The impact of different dose-response models on risk estimates is particularly pronounced when introducing heterogeneity in the population exposure distribution.

Ancillary